Dianthus Therapeutics, Inc.
NASDAQ:DNTHBiotechnology
-$1.03 today
- Market cap
- $4.73B
- Beta
- 0.07
- P/E (TTM)
- -343.0
- EPS (TTM)
- -$0.24
Volume 0.84M
Average 0.82M
DNTH EBITDA Margin
EBITDA as a percentage of revenue.
Dianthus Therapeutics, Inc.NASDAQ: DNTH
EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026
EBITDA Margin widens to -6584.5%
EBITDA Margin was -6584.5% in Q2 FY2026, up 9752.3 pp from a year earlier. On a trailing-twelve-month basis it was -1550.9%, up 804.4 pp year over year. Over 3 fiscal years it narrowed by 7510.8 pp.
Context
- EBITDA Margin widened in 1 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 11 analysts of -5108.0% for the fiscal year ending Dec 2026, up from -7952.3% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -6584.5%+2218.5 pp QoQ
- Last fiscal yearDec 2025
- -7952.3%-6596.1 pp YoY
- LTMJun 2026
- -1550.9%+804.4 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -7952.3%
- Year-over-year change
- -6596.1pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -7952.3% | -6596.1pp |
| FY2024 | 2024-12-31 | -1356.2% | +172.5pp |
| FY2023 | 2023-12-31 | -1528.7% | -1087.2pp |
| FY2022 | 2022-12-31 | -441.5% | +309.8pp |
| FY2021 | 2021-12-31 | -751.3% | — |
EBITDA Margin vs competitors
How DNTH compares with its peers on the latest reported figures
- DNTH's LTM Jun 2026 EBITDA Margin of -1550.9% is the 3rd highest of the 7 companies compared; the peer median is -6586.3%.
- Its year-over-year change of +804.4 pp is the highest of 5, against a peer median of -6398.7 pp.
- Over three fiscal years its change of -7510.8 pp compares with a peer median of +616.4 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 41.2% | — | +616.4 pp | |
| LTM Mar 2026 | 25.2% | +93.4 pp | +1052.7 pp | |
| LTM Jun 2026 | -1550.9% | +804.4 pp | -7510.8 pp | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | -5986.3% | -3970.2 pp | — |
| LTM Sep 2026 | -7186.4% | — | — | |
| LTM Mar 2026 | -8932.3% | -8827.3 pp | -4917.5 pp | |
| FY2025 | -85279.7% | -85223.0 pp | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
ARTVArtiva Biotherapeutics, Inc. | FY2025 | — | — | — |
| Peer median (excluding DNTH) | -6586.3% | -6398.7 pp | +616.4 pp | |
Competitors are the stored peer set for DNTH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.48M | 6.42M | 2.83M | 6.24M | 2.04M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 1.48M | 6.42M | 2.83M | 6.24M | 2.04M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 12.61M | 29.38M | 32.84M | 83.11M | 145.64M |
| Selling, General & Admin | 1.96M | 6.74M | 18.16M | 24.99M | 34.33M |
| Operating Expenses | 14.56M | 36.12M | 51M | 108.1M | 179.97M |
| Depreciation & Amortization | 2.02M | 147K | 355K | 412K | 428K |
| EBITDA | (11.09M) | (28.33M) | (43.2M) | (84.56M) | (161.91M) |
| EBITDA Margin | -751.3% | -441.5% | -1528.7% | -1356.2% | -7952.3% |
| Operating Income | (13.09M) | (29.71M) | (48.17M) | (101.86M) | (177.93M) |
| Operating Margin | -886.6% | -462.9% | -1704.7% | -1633.7% | -8739.3% |
| Interest Income | 100K | 1.15M | 4.76M | 17.37M | 16.12M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (23K) | 1.23M | 4.62M | 16.9M | 15.6M |
| Income Before Tax | (13.11M) | (28.48M) | (43.56M) | (84.97M) | (162.34M) |
| Pre-Tax Margin | -888.1% | -443.8% | -1541.2% | -1362.8% | -7973.3% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (13.11M) | (28.48M) | (43.56M) | (84.97M) | (162.34M) |
| Net Margin | -888.1% | -443.8% | -1541.2% | -1362.8% | -7973.3% |
| EPS (Basic) | (3.82) | (7.60) | (8.45) | (2.55) | (4.20) |
| EPS (Diluted) | (3.82) | (7.60) | (8.45) | (2.55) | (4.20) |
| Weighted Avg Shares | 3.43M | 3.75M | 5.15M | 33.31M | 37.79M |
| Weighted Avg Shares (Diluted) | 3.43M | 3.75M | 5.15M | 33.31M | 37.79M |
Dianthus Therapeutics, Inc.
NASDAQ:DNTH
Intrinsic Alpha fair value
Locked
Current Price
$83.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.